Carboplatin

SKU: orb1309915

Description

Carboplatin

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 41575-94-4
• MW: 371.25
• Purity: 99.72%
• Formula: C₆H₁₂N₂O₄Pt
• SMILES: [NH2-].[NH2-].[Pt+4].[O-]C(=O)C1(CCC1)C([O-])=O
• Target: DNA/RNA Synthesis,DNA Alkylator/Crosslinker,Autophagy
• Solubility: DMF:1 mg/mL (2.69 mM);H2O:12.5 mg/mL (33.67 mM)

Bioactivity

• Target IC50:
  Brca2 cells:1.9 μM|SKOV3 cells:12.442 μM|A2780 cells:6.177 μM|IGROV1 cells:2.233 μM|HX62 cells:116.068 μM|Brca1 cells:3.4 μM
• In Vivo:
  METHODS: To test the antitumor activity in vivo, Carboplatin (20 mg/kg) was injected intravenously into the tail of BALB/c (nu/nu) mice harboring human RB tumor Y79 every three days for one or two weeks. RESULTS: Carboplatin successfully inhibited the growth of human RB xenografts in vivo. METHODS: To detect anti-tumor activity in vivo, Carboplatin (25-75 mg/kg) was injected intraperitoneally into immunodeficient mice bearing EOC xenograft tumors once a week for six weeks. RESULTS: OV1946 and OV4453 were sensitive to Carboplatin, OV90 and OV4485 showed moderate response, and TOV21G and TOV112D were resistant.
• In Vitro:
  METHODS: 5637 cells were treated with Carboplatin (0-10000 μM) for 4 h. Cell viability was determined by MTT. RESULTS: Carboplatin showed a dose-dependent cell killing effect with an IC50 value of 289.3±2.90 μM. METHODS: Human RB tumor cells Y79 were treated with Carboplatin (20-80 μg/mL) for 2 days, and apoptosis was detected by Flow Cytometry. RESULTS: Carboplatin induced an increase in the rate of early apoptosis.
• Cell Research:
  3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet. (Only for Reference)

Storage & Handling

• Storage: keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CBDCA, Crosslinker, DNA Alkylator, DNA Alkylator/Crosslinker, DNAAlkylator, DNASynthesis, DNA Synthesis, DNA synthesis, DNA/RNA Synthesis, Carboplatin, Autophagy, NSC 241240, NSC241240, NSC-241240, JM8, JM-8, JM 8, inhibit, Inhibitor, RNASynthesis, RNA Synthesis

Compound Identifiers

PubChem CID

73554252